Skip to main content

Table 1 Clinico-pathological and molecular features of 1915 patients who were included in our analyses and underwent surgery between 1998 and 2010 (column A), highlighting the features of 6 patients with MC occurring during the first 10 years of follow up and considered in the analyses (column B)

From: Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients

Collected parameters Column A Column B
Patients n = 1915 (%) Patients with MC n = 6 (%)
Age at diagnosis of BC
 - <50 years 338 (17.6 %) 6 (100 %)
 - ≥50 years 1577 (82.4 %) 0
Treatment
 - T (umorectomy) 1400 (73.1 %) 2 (33.3 %)
 - M (astectomy) 515 (26.9 %) 4 (66.7 %)
Histological type
 - IDC 1154 (60.3 %) 5 (83.3 %)
 - ILI 348 (18.2 %) 0
 - Mixed IDC-ILI 146 (7.6 %) 1 (16.7 %)
 - Others 267 (13.9 %) 0
Histological grade
 - G1 564 (29.5 %) 0
 - G2 908 (47.4 %) 2 (33.3 %)
 - G3 435 (22.7 %) 4 (66.7 %)
 - Not available 8 (0.4 %) 0
Tumor size
 - ≤ 15 mm 1019 (53.2 %) 0
 - > 15 mm 890 (46.5 %) 6 (100 %)
 - Not available 6 (0.3 %) 0
Vascular invasion
 - No 1271 (66.4 %) 1 (16.7 %)
 - Yes 626 (32.7 %) 5 (83.3 %)
 - Not available 18 (0.9 %) 0
pT stage
 - pT1 1342 (70.1 %) 1 (16.7 %)
 - pT2 493 (25.7 %) 5 (83.3 %)
 - pT3-4 76 (4 %) 0
 - Not available 4 (0.2 %) 0
pN stage
 - Negative (including ITC/micrometastasis)/pN0 1335 (69.7 %) 1 (16.7 %)
 - from 1 to 3 nodes positive/pN1 338 (17.7 %) 2 (33.3 %)
 - >3 nodes positive/pN2-pN3 167 (8.7 %) 3 (50 %)
 - Not available 75 (3.9 %) 0
cM stage at diagnosis
 cM0 1889 (98.6 %) 4 (66.7 %)
 cM1 26 (1.4 %) 2 (33.3 %)
Bone metastases
 - no 1818 (94.9 %) 3 (50 %)
 - yes 97 (5.1 %) 3 (50 %)
Brain metastases
 - no 1898 (99.1 %) 1 (16.7 %)
 - yes 17 (0.9 %) 5 (83.3 %)
Metastases in other site, NAS
 - no 1686 (88 %) 0
 - yes 229 (12 %) 6 (100 %)
ER status
 Negative 190 (9.9 %) 3 (50 %)
 Positive 1693 (88.4 %) 3 (50 %)
 Not available 32 (1.7 %) 0
PR status
 - Negative 256 (13.4 %) 2 (33.3 %)
 - Positive 1365 (71.3 %) 3 (50 %)
 - Not available 294 (15.4 %) 1 (16.7 %)
Ki67
 - <20 % 1103 (57.6 %) 2 (33.3 %)
 - ≥20 % 741 (38.7 %) 4 (66.7 %)
 - Not available 71 (3.7 %) 0
HER2
 - negative 1662 (86.8 %) 3 (50 %)
 - positive 151 (7.9 %) 3 (50 %)
 - Not available 101 (5.3 %) 0
Neoadjuvant chemotherapy
 - No 1836 (95.9 %) 3 (50 %)
 - Yes 79 (4.1 %) 3 (50 %)
Adjuvant treatment
 - Chemotherapy 722 (37.7 %) 4 (66.7 %)
 - Radiotherapy 1352 (70.6 %) 1 (16.7 %)
 - Hormone therapy 1520 (79.4 %) 2 (33.3 %)
  1. IDC Infiltrating ductal carcinoma, ILC Infiltrating lobular carcinoma, G histological tumor grade [28], ITC isolated tumor cells